BR112015029056A2 - composto, e pílula farmacêutica ou pastilha implantável por via subcutânea para tratar um ser humano que sofre de endometriose - Google Patents
composto, e pílula farmacêutica ou pastilha implantável por via subcutânea para tratar um ser humano que sofre de endometrioseInfo
- Publication number
- BR112015029056A2 BR112015029056A2 BR112015029056A BR112015029056A BR112015029056A2 BR 112015029056 A2 BR112015029056 A2 BR 112015029056A2 BR 112015029056 A BR112015029056 A BR 112015029056A BR 112015029056 A BR112015029056 A BR 112015029056A BR 112015029056 A2 BR112015029056 A2 BR 112015029056A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- endometriosis
- treat
- tablet
- pill
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
Abstract
resumo composto, e pílula farmacêutica ou pastilha implantável por via subcutânea para tratar um ser humano que sofre de endometriose a presente invenção refere-se a um composto que compreende uma porção de nsaid e pelo menos uma dentre uma porção de progestina e uma porção de progesterona. o composto pode tomar, por exemplo, a forma de uma pílula ou pastilha (para uso interno oral ou para implantação subcutânea), uma solução injetável ou um supositório. o composto é destinado ao uso no tratamento de indivíduos que têm ou estão em risco aumentado especialmente risco determinado pela genética - de desenvolver endometriose. o composto pode também ser usado para tratar outras doenças ou como um contraceptivo. 1/1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361825587P | 2013-05-21 | 2013-05-21 | |
PCT/US2014/038601 WO2014189836A1 (en) | 2013-05-21 | 2014-05-19 | Therapeutic and method of use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015029056A2 true BR112015029056A2 (pt) | 2017-07-25 |
Family
ID=51934015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015029056A BR112015029056A2 (pt) | 2013-05-21 | 2014-05-19 | composto, e pílula farmacêutica ou pastilha implantável por via subcutânea para tratar um ser humano que sofre de endometriose |
Country Status (9)
Country | Link |
---|---|
US (4) | US9161941B2 (pt) |
EP (2) | EP3943079A1 (pt) |
JP (1) | JP2016520590A (pt) |
KR (1) | KR20160013098A (pt) |
AU (2) | AU2014268779A1 (pt) |
BR (1) | BR112015029056A2 (pt) |
CA (1) | CA2913149A1 (pt) |
MX (1) | MX2015016038A (pt) |
WO (1) | WO2014189836A1 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8641738B1 (en) | 2004-10-28 | 2014-02-04 | James W. Ogilvie | Method of treating scoliosis using a biological implant |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
US9161941B2 (en) | 2013-05-21 | 2015-10-20 | Predictive Therapeutics, LLC | Therapeutic and method of use |
US10319475B1 (en) | 2014-06-13 | 2019-06-11 | Enigami Systems, Inc. | Method and apparatus for determining relationships between medications and symptoms |
KR102662025B1 (ko) | 2015-06-18 | 2024-05-02 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 에스테트롤 성분을 함유하는 구강분해성 투여 단위 |
MD3310346T2 (ro) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Comprimată orodispersabilă ce conține estetrol |
RS61812B1 (sr) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Oralno-disperzibilna tableta koja sadrži estetriol |
AU2016280863B2 (en) | 2015-06-18 | 2021-04-01 | Estetra Srl | Orodispersible dosage unit containing an estetrol component |
US11191794B1 (en) | 2016-02-08 | 2021-12-07 | Jeff Nordahl | Packaged hemp products formed from raw cannabis |
US11172698B1 (en) | 2016-02-08 | 2021-11-16 | Jeff Nordahl | Pasteurized juice formed from raw cannabis |
US9956174B1 (en) | 2016-02-08 | 2018-05-01 | Jeff Nordahl | Packaged frozen cubes of cannabis juice purée with added decarboxylated cannabis material |
US11779622B1 (en) | 2016-02-08 | 2023-10-10 | Jeff Nordahl | Packaged raw cannabis powder |
CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
US20200035118A1 (en) | 2018-07-27 | 2020-01-30 | Joseph Pandolfino | Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes |
US10897925B2 (en) | 2018-07-27 | 2021-01-26 | Joseph Pandolfino | Articles and formulations for smoking products and vaporizers |
WO2022012551A1 (en) * | 2020-07-14 | 2022-01-20 | Natur-Tech Pharmacal Co., Ltd | Compositions and uses thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04178359A (ja) * | 1990-07-01 | 1992-06-25 | Kuraray Co Ltd | テトラサイクリン誘導体 |
US20020160988A1 (en) * | 2001-02-20 | 2002-10-31 | Israel Institute For Biological Research | Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof |
US20050101579A1 (en) | 2003-11-06 | 2005-05-12 | Shippen Eugene R. | Endometriosis treatment protocol |
US8641738B1 (en) | 2004-10-28 | 2014-02-04 | James W. Ogilvie | Method of treating scoliosis using a biological implant |
US8123787B2 (en) | 2004-10-28 | 2012-02-28 | Ogilvie James W | Method of treating scoliosis using a biological implant |
JP2006248904A (ja) * | 2005-03-08 | 2006-09-21 | Yoshihiro Futamura | アルファ−リポ酸と多価不飽和脂肪酸の結合体からなるラジカル消去作用を呈する抗炎症剤、それを含有する食品製剤、化粧品製剤 |
DE602006012972D1 (de) | 2005-04-28 | 2010-04-29 | Wyeth Corp | Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung |
US8932993B1 (en) | 2007-06-11 | 2015-01-13 | Juneau Biosciences, LLC. | Method of testing for endometriosis and treatment therefor |
US20080306034A1 (en) | 2007-06-11 | 2008-12-11 | Juneau Biosciences, Llc | Method of Administering a Therapeutic |
WO2009075838A2 (en) * | 2007-12-10 | 2009-06-18 | Meditrina Pharmaceuticals, Inc. | Treatment of menorrhagia with aromatase inhibitor |
AU2008341138A1 (en) | 2007-12-20 | 2009-07-02 | Teva Women's Health, Inc. | Dosage regimens and pharmaceutical compositions and packages for emergency contraception |
US9434991B2 (en) | 2013-03-07 | 2016-09-06 | Juneau Biosciences, LLC. | Method of testing for endometriosis and treatment therefor |
US9161941B2 (en) | 2013-05-21 | 2015-10-20 | Predictive Therapeutics, LLC | Therapeutic and method of use |
US20170112881A1 (en) | 2016-01-06 | 2017-04-27 | Predictive Therapeutics, LLC | Method of Treating Endometriosis |
-
2014
- 2014-05-19 US US14/281,127 patent/US9161941B2/en active Active
- 2014-05-19 WO PCT/US2014/038601 patent/WO2014189836A1/en active Application Filing
- 2014-05-19 EP EP21194777.5A patent/EP3943079A1/en not_active Withdrawn
- 2014-05-19 KR KR1020157035992A patent/KR20160013098A/ko not_active Application Discontinuation
- 2014-05-19 CA CA2913149A patent/CA2913149A1/en not_active Abandoned
- 2014-05-19 AU AU2014268779A patent/AU2014268779A1/en not_active Abandoned
- 2014-05-19 US US14/281,172 patent/US9149499B1/en active Active
- 2014-05-19 MX MX2015016038A patent/MX2015016038A/es unknown
- 2014-05-19 EP EP14801452.5A patent/EP2999474A4/en not_active Withdrawn
- 2014-05-19 JP JP2016514989A patent/JP2016520590A/ja active Pending
- 2014-05-19 BR BR112015029056A patent/BR112015029056A2/pt not_active Application Discontinuation
-
2015
- 2015-10-05 US US14/875,656 patent/US10213439B2/en not_active Expired - Fee Related
-
2019
- 2019-01-11 US US16/245,564 patent/US10744143B2/en active Active
- 2019-10-10 AU AU2019246858A patent/AU2019246858A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2999474A1 (en) | 2016-03-30 |
US20160022696A1 (en) | 2016-01-28 |
US9161941B2 (en) | 2015-10-20 |
KR20160013098A (ko) | 2016-02-03 |
EP3943079A1 (en) | 2022-01-26 |
US10744143B2 (en) | 2020-08-18 |
US9149499B1 (en) | 2015-10-06 |
US20190142843A1 (en) | 2019-05-16 |
US20140348957A1 (en) | 2014-11-27 |
AU2014268779A1 (en) | 2016-01-21 |
CA2913149A1 (en) | 2014-11-27 |
JP2016520590A (ja) | 2016-07-14 |
AU2019246858A1 (en) | 2019-10-31 |
MX2015016038A (es) | 2016-03-21 |
WO2014189836A1 (en) | 2014-11-27 |
EP2999474A4 (en) | 2016-12-28 |
US10213439B2 (en) | 2019-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015029056A2 (pt) | composto, e pílula farmacêutica ou pastilha implantável por via subcutânea para tratar um ser humano que sofre de endometriose | |
AR097178A1 (es) | Diagnóstico y terapias anticáncer que comprenden células madre cancerosas | |
MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
BR112015026006A2 (pt) | métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor | |
BR112015023910A2 (pt) | terapia envolvendo anticorpos contra claudin 18.2 para tratamento de câncer | |
BR112016028964A2 (pt) | métodos de tratamento com antagonistas contra pd-1 e pd-l1 em combinação com terapia de radiação | |
BR112016012410A2 (pt) | conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica | |
TN2016000094A1 (en) | Inhibitors of bruton's tyrosine kinase. | |
BR112015027682A2 (pt) | Uso de sobetirome no tratamento de doenças ou condições associadas com a desmielinização ou mielinização insuficiente | |
PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
BR112014016672A8 (pt) | compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo | |
EA201591679A1 (ru) | Способ нетоксического лечения абстиненции, вызванной лекарственным средством | |
MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
BR112016000546A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
MX2019006867A (es) | Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de integrina. | |
NZ606765A (en) | Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract | |
TR201911232T4 (tr) | Otoimmünite gelişimine yönelik coriolus versicolorun ekstraktını içeren topikal bileşimler. | |
BR112017000285A2 (pt) | métodos de tratamento da profilaxia viral e kits de profilaxia de pré-exposição | |
BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
BR112017014361A2 (pt) | métodos para aperfeiçoamento de terapia celular | |
BR112015022982A2 (pt) | inibidores macrocíclicos de rip2 quinase | |
EA201790352A1 (ru) | Терапевтическое лечение на основе анаморелина | |
PH12015502128A1 (en) | Novel dosing regimens of celgosivir for the treatment of dengue | |
MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
NZ754328A (en) | Marker for acid sphingomyelinase disorders and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |